Source: Celgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing. A California whistleblower case, however, has moved forward with the unsealing of thousands of pages of new documents that attorneys for a former sales…...

Source: FierceBiotech The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering. The Durham, NC-based company, which is around a decade old, is working on nitric oxide based therapies for dermatologic indications, including acne. According to its SEC-1 filing, the…...

Source: Allergan ($AGN) thinks facial injectable Kybella has the potential to one day bank Botox-level sales. And the company is starting up a couple new studies to help it get there. The Dublin drugmaker is initiating trials of the med in bra-line fat and fat around the knees and ankles,…...

Source: Reuters U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc (VRX.N) over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales, the Wall Street Journal reported on Wednesday. Lawyers at the U.S. Attorney's Manhattan office are trying to…...

Source: Real Money Valeant Pharmaceuticals' (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels -- especially as the drugmaker's roughly $31 billion debt package did not come without strings attached. Lender-friendly covenants, such…...